PRISTIQ
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $10,389 | 2 | 2 |
| 2021 | $4,500 | 1 | 1 |
| 2020 | $6,433 | 2 | 2 |
| 2018 | $780.00 | 1 | 1 |
| 2017 | $44,755 | 30 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,002 | 11 | 53.8% |
| Unspecified | $19,370 | 22 | 29.0% |
| Consulting Fee | $11,400 | 2 | 17.1% |
| Travel and Lodging | $84.70 | 1 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 6 MONTH OPEN LABEL MULTI CENTER FLEXIBLE DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE DVS SR TABLETS IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | PFIZER INC. | $8,184 | 0 |
| A PHASE IV MULTICENTER RANDOMIZED 8WEEK DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY OF 2 FIXED DOSES 50 AND 100 MGDAY OF DESVENLAFAXINE SUCCINATE SUSTAINEDRELEASE FORMULATION DVS SR IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | PFIZER INC. | $4,500 | 0 |
| A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED FLUOXETINEREFERENCED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE DVS SR IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | PFIZER INC. | $2,311 | 0 |
| A 6MONTH OPENLABEL MULTICENTER FLEXIBLE DOSE EXTENSION STUDY TO THE B2061032 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE DVS SR TABLETS IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | PFIZER INC. | $1,950 | 0 |
| DESVENLAFAXINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,900 | 1 |
| A PHASE 1 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED ADAPTIVE MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF AAB003 PF05236812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMERS DISEASE | PFIZER INC. | $500.00 | 0 |
| A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF DESVENLAFAXINE SUCCINATE SUSTAINEDRELEASE DVS SR IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | PFIZER INC. | $25.00 | 0 |
Top Doctors Receiving Payments for PRISTIQ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Blue Bell, PA | $17,470 | 21 |
| , MD | Psychiatry | Philadelphia, PA | $8,933 | 2 |
| , MD | Psychiatry | Austin, TX | $7,085 | 2 |
| , MD | General Practice | Rochester, NY | $6,400 | 2 |
| , M.D | Cardiovascular Disease | Durham, NC | $6,009 | 1 |
| , MD | Psychiatry | Providence, RI | $4,500 | 1 |
| , MD | Internal Medicine | New Orleans, LA | $4,380 | 1 |
| , MD | Child & Adolescent Psychiatry | Baltimore, MD | $3,200 | 1 |
| , M.D | Psychiatry | Oklahoma City, OK | $3,200 | 1 |
| , MD | Child & Adolescent Psychiatry | Tucson, AZ | $2,280 | 2 |
| , MD | Psychiatry | New York, NY | $1,900 | 1 |
| William Murphy | — | Overland Park, KS | $1,500 | 1 |
Manufacturing Companies
- PFIZER INC. $40,350
- PFIZER INTERNATIONAL LLC $26,507
Product Information
- Type Drug
- Total Payments $66,857
- Total Doctors 11
- Transactions 36
About PRISTIQ
PRISTIQ is a drug associated with $66,857 in payments to 11 healthcare providers, recorded across 36 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INTERNATIONAL LLC.
Payment data is available from 2017 to 2022. In 2022, $10,389 was paid across 2 transactions to 2 doctors.
The most common payment nature for PRISTIQ is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($36,002, 53.8% of total).
PRISTIQ is associated with 7 research studies, including "A 6 MONTH OPEN LABEL MULTI CENTER FLEXIBLE DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE DVS SR TABLETS IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER" ($8,184).